Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

18 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Cost-effectiveness models for Alzheimer's disease and related dementias: IPECAD modeling workshop cross-comparison challenge.
Handels RLH, Green C, Gustavsson A, Herring WL, Winblad B, Wimo A, Sköldunger A, Karlsson A, Anderson R, Belger M, Brück C, Espinosa R, Hlávka JP, Jutkowitz E, Lin PJ, Mendez ML, Mar J, Shewmaker P, Spackman E, Tafazzoli A, Tysinger B, Jönsson L; IPECAD modeling workshop 2020 participants. Handels RLH, et al. Among authors: herring wl. Alzheimers Dement. 2023 May;19(5):1800-1820. doi: 10.1002/alz.12811. Epub 2022 Oct 25. Alzheimers Dement. 2023. PMID: 36284403 Free PMC article.
New International Pharmaco-Economic Collaboration on Alzheimer's Disease (IPECAD) Open-Source Model Framework for the Health Technology Assessment of Early Alzheimer's Disease Treatment: Development and Use Cases.
Handels R, Herring WL, Grimm S, Sköldunger A, Winblad B, Wimo A, Jönsson L. Handels R, et al. Among authors: herring wl. Value Health. 2024 Jul 31:S1098-3015(24)02790-6. doi: 10.1016/j.jval.2024.07.009. Online ahead of print. Value Health. 2024. PMID: 39094686 Free article.
IPECAD Modeling Workshop 2023 Cross Comparison Challenge on Cost-Effectiveness Models in Alzheimer's Disease.
Handels R, Herring WL, Kamgar F, Aye S, Tate A, Green C, Gustavsson A, Wimo A, Winblad B, Sköldunger A, Raket LL, Stellick CB, Spackman E, Hlávka J, Wei Y, Mar J, Soto-Gordoa M, de Kok I, Brück C, Anderson R, Pemberton-Ross P, Urbich M, Jönsson L. Handels R, et al. Among authors: herring wl. Value Health. 2024 Oct 7:S1098-3015(24)02857-2. doi: 10.1016/j.jval.2024.09.006. Online ahead of print. Value Health. 2024. PMID: 39384068 Free article.
Cost-Effectiveness of Respiratory Syncytial Virus Preventive Interventions in Children: A Model Comparison Study.
Li X, Hodgson D, Flaig J, Kieffer A, Herring WL, Beyhaghi H, Willem L, Jit M, Bilcke J, Beutels P; REspiratory Syncytial virus Consortium in EUrope (RESCEU) Investigators. Li X, et al. Among authors: herring wl. Value Health. 2023 Apr;26(4):508-518. doi: 10.1016/j.jval.2022.11.014. Epub 2022 Nov 26. Value Health. 2023. PMID: 36442831 Free article.
Cost-Effectiveness of Lovotibeglogene Autotemcel (Lovo-Cel) Gene Therapy for Patients with Sickle Cell Disease and Recurrent Vaso-Occlusive Events in the United States.
Herring WL, Gallagher ME, Shah N, Morse KC, Mladsi D, Dong OM, Chawla A, Leiding JW, Zhang L, Paramore C, Andemariam B. Herring WL, et al. Pharmacoeconomics. 2024 Jun;42(6):693-714. doi: 10.1007/s40273-024-01385-9. Epub 2024 Apr 29. Pharmacoeconomics. 2024. PMID: 38684631 Free PMC article.
18 results